Jacobson Pharma Corporation Limited Overview
Jacobson Pharma is Hong Kong's largest locally based, vertically integrated generic-drug manufacturer. It runs nine licensed pharmaceutical production facilities in Hong Kong, an SAP-driven central warehouse and its own truck fleet, regulatory, quality and sales operations. Around 97% of revenue comes from Hong Kong, and roughly half from one major customer, almost certainly the Hospital Authority, which runs the public hospital system. Since spinning off and then fully distributing its branded consumer-health arm (JBM Healthcare) in 2021–2023, it has become a focused "essential medicines and specialty drugs" company. Its growth levers are a 241-product generics pipeline, an aggressive in-licensing programme (46 deals in FY2026), biosimilars, and a niche position as one of only two licensed CAR-T handlers in Hong Kong. Earnings quality is high: 43% gross margin, 34.5% adjusted EBITDA margin, and HK$301.6m attributable profit in FY2026. The equity trades at about 6.4x trailing earnings, with a founder who controls about 70% of the shares.
Company's own description (AR FY2026, paraphrased)
The company calls itself a leading Hong Kong pharmaceutical company that is vertically integrated across research, development, production, sale and distribution of essential medicines and specialty drugs. It says it is a major provider of generic drugs in Hong Kong, with one of the widest sales and distribution reaches into both the Public Sector (Hospital Authority and Department of Health) and the Private Sector (private hospitals, clinics, doctors in private practice and registered pharmacies). It is also expanding into selected Asian markets. It runs 9 licensed production facilities in Hong Kong and manages its own warehousing, logistics, regulatory, quality control, and sales and marketing functions. Its stated vision is to become a leading player in essential medicines, specialty drugs and healthcare solutions in Greater China and Asia.
The AR FY2026 lists four competitive strengths:
-
Leadership across a wide range of essential and specialty drugs in Hong Kong, including respiratory, cardiovascular, central nervous system (CNS), gastrointestinal and oral anti-diabetic medicines, with a strategic tilt toward specialty drugs and biosimilars.
-
R&D capability that the company says leads Hong Kong generic manufacturers by number of new drug registrations in recent years, plus partnerships with local and overseas research institutions.
-
Sales and distribution covering substantially all Public and Private Sector institutions and registered pharmacies.
-
Logistics infrastructure that includes a central distribution centre, a high-capacity truck fleet, and specialised vaccine and Advanced Therapy Product (ATP) cold-chain capability.
Business model and revenue model
| Revenue stream | Nature | Disclosure status |
|---|---|---|
| Manufactured generic drugs (own registrations) | Product sales to the Public Sector (mostly via tenders and contracts) and the Private Sector | Not split out; the bulk of revenue |
| In-licensed specialty drugs, biologics, biosimilars and vaccines | Product sales of partner products under exclusive HK/Macau licences | Not split out |
| Logistics, supply-chain and patient-support services (e.g., Yikaida CAR-T) | Service fees for ATP cold-chain, logistics, sales and marketing support | Not split out; believed small |
| e-Jacob Pharma2U digital ordering | Channel for product sales to 1,200+ clinics | Not a separate revenue line |
| Rental and licence income (e.g., licence of Tai Po factory space to JBM's Europharm HK) | Other income | HK$247,000 a month under the Oct 2025 agreement |
| Licensing out / royalties | — | — |
| Subscription | — | — |
Product sales make up essentially all revenue. The group reports one operating segment ("essential medicines and specialty drugs"), so the product/service/licensing mix is not publicly disclosed in numbers.
Value-chain position
Jacobson covers the full value chain for off-patent medicines in Hong Kong: formulation and pre-formulation R&D, stability studies and dossier registration with the Pharmacy and Poisons Board, PIC/S-GMP manufacturing across solid, semi-solid, liquid and sterile (eye drops and injections) dosage forms, warehousing, logistics and direct field sales. For in-licensed innovative and specialty medicines it acts as local marketing authorisation holder, importer, distributor and patient-services provider. Raw materials (active pharmaceutical ingredients and excipients) are bought from approved vendors. Material costs were 41% of cost of sales in FY2026.
Customer types and concentration
Public Sector: One customer accounted for more than 10% of revenue: HK$800.8m in FY2026 (≈51.0% of revenue), up from HK$757.2m in FY2025 (≈48.0%). The customer is not named, but given Hong Kong's market structure it is almost certainly the Hospital Authority (inference).
Private Sector: Private hospitals, general practitioners, specialists, dentists, veterinarians (through e-Jacob Pharma2U) and registered pharmacies.
Regional customers: Macau (HK$31.6m), Chinese Mainland (HK$23.3m) and other markets (HK$0.2m) in FY2026.
End markets served
Hong Kong prescription pharmaceuticals (public and private), the Macau pharmaceutical market, limited Mainland China sales (cold and flu and gastrointestinal lines), Greater Bay Area designated hospitals (Arsenic Trioxide Oral Solution approved for GBA use in 2022), and a new veterinary diagnostics niche (an in-licensed DNA test for animal cancer treatment options, FY2026).
Independent characterisation
Jacobson is best seen as a Hong Kong-centric, quasi-utility supplier of essential generics to a single-payer public system, with an expanding specialty in-licensing "platform" on top. Its economics rest on registration barriers (Hong Kong's small market discourages multinational generic makers from registering low-value molecules), tender scale and local manufacturing credibility. The 2023 removal of the consumer-brands business (JBM) made the earnings stream lower in growth but more defensive and higher in margin. The main strategic questions are (i) how dependent it is on Hospital Authority tender pricing, (ii) whether in-licensed specialty and biosimilar products can offset seasonal volatility in cold and flu demand, and (iii) whether the HK$600m+ Tai Po smart-factory capex will earn its cost of capital.
Strategy
Stated strategy (AR FY2026, paraphrased)
Vision: To be a leading player in essential medicines, specialty drugs and healthcare solutions in Greater China and Asia.
Mission: Create sustainable value through accessible, cost-effective products that improve patient outcomes. Enrich communities through responsible and inclusive practices. Build shareholder value.
Culture: "Challenge, Connect, Commit", operating as "one company, one team".
Three strategic pillars: (Chairman's Statement): portfolio expansion, innovation, manufacturing excellence.
Growth engines: cited by management: the chronic disease and specialty medicines portfolio, in-licensed products, biosimilars and biologics, advanced therapies (CAR-T), digital procurement, and Hong Kong primary-care reform.
Annual report theme for FY2026: "Steadfast Commitment to Growth Strategies and Execution Excellence."
Strategic initiatives in the last 24 months
| Initiative | Start | Description and status | Targets / metrics | Source |
|---|---|---|---|---|
| Tai Po InnoPark smart factory | Feb 2025 | Ten AI- and robotics-enabled production lines (sterile eye drops, solid dosage, oral liquids). Supported by the HK Government's New Industrialisation Acceleration Scheme. Main contractor works contract HK$607.2m (1 Apr 2026). | First line trial H1 2027; full operation H1 2029 | AR FY2026; HKEX |
| In-licensing programme | Ongoing | 20 exclusive in-licences in FY2025; 46 in FY2026 (specialty drugs, biologics, vaccines, advanced therapies) | No numeric target | AR FY2025; AR FY2026 |
| Biosimilars and biologics push | FY2026 | Prefilled syringe and pen formats | — | AR FY2026 |
| CAR-T and ATP logistics (Yikaida) | Feb 2025 | End-to-end supply chain in HK and Macau with Fosun Pharma and Fosun Kairos | 4 patients treated by Mar 2026 | AR FY2026 |
| e-Jacob Pharma2U | Ongoing | Digital B2B ordering; new features, analytics, loyalty schemes | Over 1,200 clinics | AR FY2026 |
| R&D pipeline expansion | Ongoing | Pipeline 219 (Mar 2025) → 241 (Mar 2026); 23 approvals in FY2026 | — | AR FY2025; AR FY2026 |
| Veterinary entry | FY2026 | In-licensed DNA test for animal cancer treatment options | — | AR FY2026 |
| Fotan facility revamp | FY2025–26 | Revamped facilities; oral solid dosage operations started at a subsidiary | Oral liquid output +65.5%; semi-solid output ×4.7 | AR FY2026 |
| Community Pharmacy Programme / Community Drug Formulary participation | FY2027 | Positioning for the government's CPP, phased in from Q4 2026 | — | AR FY2026 |
| Greater Bay Area | Ongoing | GBA designated-hospital access (Arsenic Trioxide Oral Solution); regional integration | — | AR FY2026; FY2023 interim |
| ESG "5 to Thrive" | Since FY2023 | Five pillars aligned with UN SDGs: Corporate Governance, Product Responsibility, Societal Engagement, Environmental Stewardship, Employee Commitment | Reduction targets set for GHG, waste, energy and water; numbers in the ESG report, not captured | AR FY2026 |
| Clinical-stage asset | 2,026 | The FY2025 results release mentioned a global Phase III trial to start in 2026, targeting market approval in 2028. The product was not identified in the extract reviewed, and AR FY2026 did not repeat it. | Approval target 2028 | FY2025 results release (Quamnet) |
| Cost discipline | FY2026 | Process optimisation and cost control credited for protecting profit | Not quantified | AR FY2026 |
Medium-term financial targets and guidance
No quantitative guidance has been published. Management gives no revenue, margin, EPS or capex targets. Qualitative outlook (AR FY2026): optimism based on ageing demographics, chronic disease prevalence, primary-care reform (District Health Centres, CDCC Pilot Scheme, CDF, CPP from Q4 2026), patent expiries, a faster new-drug evaluation mechanism (phased in from March 2026), and GBA integration. The dividend policy aims for "reasonably stable and consistent" dividends, normally paid twice a year, while keeping reserves for M&A.
Products & Services
The company does not publish SKU-level revenue. The catalogue below is built from AR FY2026, AR FY2025 and interim disclosures. Pricing is set through Hospital Authority tenders and private-market negotiation; product-level prices are not publicly disclosed.
Own-manufactured generics by therapeutic area
| Therapeutic area | Named products / description | Target customer | Recent activity | Source |
|---|---|---|---|---|
| Cardiovascular – antihypertensives | Olmesartan tablets (launched H1 FY2023); combination antihypertensives added | Public and Private Sectors, chronic-care clinics | Called a key growth driver in FY2026 | FY2023 interim; AR FY2026 |
| Cardiovascular – lipid-lowering | Atorvastatin tablets (launched H1 FY2023) | Private clinics; Public tenders | Strong private-market demand in FY2026 | FY2023 interim; AR FY2026 |
| Cardiovascular – anticoagulants | Innovative anticoagulants added through in-licensing | Hospitals | Added in FY2026 | AR FY2026 |
| Central nervous system | Anxiolytics, hypnotics, ADHD medications, neuropathic pain products | Psychiatric services, private practice | New public tenders won for neuropathic pain in FY2026 | AR FY2026 |
| Oncology and supportive care | Arsenic Trioxide Oral Solution (oral APL therapy; first HK-made specialty drug approved for GBA designated hospitals); expanded chemotherapy range | HA oncology units; GBA hospitals | Continued strong performance; oncology tender wins in FY2026 | AR FY2026; FY2023 interim |
| Respiratory / cold and flu / cough | Cold and flu and cough suppressant preparations, including paediatric formulations | Public and Private Sectors; Mainland | Sales fell in FY2026 as the flu season normalised | AR FY2026 |
| Gastrointestinal | GI product range | Public and private; Mainland | Mainland GI demand fell in FY2026 | AR FY2026 |
| Oral anti-diabetics | Diabetes therapies | Chronic-care settings | Supported by CDCC scheme demand | AR FY2026 |
| Ophthalmology (sterile) | Eye drops (PIC/S GMP sterile line); 10 future Tai Po lines include sterile eye drops | Hospitals and clinics | Eye-drop output +7.8% YoY in FY2026 | AR FY2026 |
| Dermatology / topical | Semi-solid formulations | Clinics and pharmacies | Semi-solid output up about 4.7-fold in FY2026 | AR FY2026 |
| Oral liquids | Oral solutions, including specialty leukaemia oral liquids developed with a medical school | Hospitals | Oral-liquid output at one subsidiary +65.5% in FY2026 | AR FY2026 |
| Sterile injectables | Injection line (PIC/S GMP) | Hospitals | — | FY2022 AR |
In-licensed specialty products, biologics, biosimilars and vaccines
| Category | Description | Count / timing | Source |
|---|---|---|---|
| Specialty drugs (exclusive in-licences) | Oncology, rheumatology, haematology, gastroenterology, cardiology, rare diseases | 20 agreements in FY2025 | AR FY2025 |
| Specialty drugs, biologics, vaccines, advanced therapies | Immunology, rheumatology, oncology, haematology, cardiology, neurology, infectious disease, supportive care | 46 agreements in FY2026 | AR FY2026 |
| Biosimilars and biologics | Pre-filled syringe and pre-filled pen formats to improve adherence | Expanding in FY2026; individual molecules not disclosed | AR FY2026 |
| Influenza vaccines | A full range of influenza vaccines added | FY2026 | AR FY2026 |
| Veterinary diagnostics | In-licensed DNA testing service to guide treatment options for animal cancer; described as an entry point into animal health | FY2026 | AR FY2026 |
Licensors are described only as "leading global pharmaceutical partners". Individual counterparties and molecules are not publicly disclosed.
Services and platforms
| Offering | Description | Customers / metrics | Launch | Source |
|---|---|---|---|---|
| Yikaida (axicabtagene ciloleucel) supply-chain and patient care | End-to-end ATP cold chain, logistics, sales and marketing support for Fosun Kairos's CAR-T therapy for relapsed or refractory DLBCL in Hong Kong and Macau. Avoids shipping patient material abroad. | 3 HK and 1 Macau patients through apheresis and reinfusion by Mar 2026 | 20 Feb 2025 (HK); Macau debut in FY2026 | AR FY2025; AR FY2026 |
| ATP logistics licence | Licensed Advanced Therapeutic Product handler; one of two authorised CAR-T handlers in Hong Kong | — | By FY2025 | AR FY2026 |
| Vaccine logistics | Specialised cold-chain storage and distribution | — | — | AR FY2026 |
| e-Jacob Pharma2U | Proprietary mobile and web e-ordering platform for healthcare professionals. Features include delivery label requests, offer selection, reward programmes and data analytics. | Over 1,200 registered clinics (GPs, specialists, dentists, vets) | Not disclosed; expanded in FY2026 | AR FY2026 |
| Contract warehousing / logistics | SAP-powered central warehouse, truck fleet | — | — | AR FY2026 |
Pipeline (31 March 2026)
| Stage | Number of products |
|---|---|
| Registration approval obtained (within pipeline) | 79 |
| Submitted, pending approval | 10 |
| Development done; in stability preparation or study | 67 |
| Formulation / pre-formulation | 25 |
| Total pipeline | 241 |
| New approvals received in FY2026 | 23 |
| Entered stability testing in FY2026 | 19 |
| Added to pipeline in FY2026 | 22 |
The stage counts sum to 181, not 241. The company does not reconcile the difference, which may be products at other stages or a different counting basis. AR FY2025 showed a similar gap (219 total vs 163 summed). Products pending approval cover CNS, cardiovascular, GI, anti-infective, pain and dermatology.
Divested consumer brands (for reference; now owned by JBM Healthcare)
Po Chai Pills, Ho Chai Kung Tji Thung San (acquired Dec 2016 for HK$568m), Tong Tai Chung Woodlok Oil, Flying Eagle Wood Lok Medicated Oil, Contractubex Scar Gel, Doan's Ointment, Saplingtan, Shiling Oil, Col-gan Tablet, and the Hong Ning Hong OTC distribution business (Mar 2017 press release). These left the group on 24 Aug 2023. Jacobson still has commercial dealings with JBM through continuing connected transactions (renewed 6 Mar 2026) and the Tai Po factory licence.
Financial Narrative
Basis warning: FY2022 and FY2023 are as originally reported, including Branded Healthcare. FY2024 is continuing operations, except that attributable profit and EPS include discontinued operations. FY2025 and FY2026 are wholly continuing. A restated FY2023 continuing figure is shown where available.
Income statement
Sources: FY2022 AR; FY2023 results announcement; FY2024 results announcement; AR FY2025; FY2026 results announcement. FY2023 cost of sales is computed as revenue minus gross profit. FY2024 profit for the year of HK$290.8m includes HK$52.4m from discontinued operations and a HK$28.2m distribution gain. Continuing profit was HK$210.2m and continuing EPS was 10.95 HK cents. The FY2024 special DPS is the in-specie JBM distribution valued at HK$1.16 per JBM share. StockAnalysis (S&P Global) shows somewhat different operating income (FY2025 HK$432.9m, FY2024 HK$311.4m) and EBITDA (FY2026 HK$506.5m) because it classifies items differently.
FY2026 income statement detail (HK$ m)
Margins and growth
Revenue CAGR (computed): On the continuing generic basis, FY2023 (restated HK$1,267.6m) to FY2026 (HK$1,569.5m) is a 3-year CAGR of about 7.4%. FY2022 to FY2026 on the generic segment basis (HK$1,191.3m to HK$1,569.5m) is a 4-year CAGR of about 7.1%. As reported, including the divested business, revenue shrank from HK$1,595.5m to HK$1,569.5m (−0.4% CAGR). This reflects the deconsolidation, not organic decline.
Commentary. The FY2022 to FY2025 period was a margin up-cycle. Gross margin rose about 500bp (38.9% to 43.9%) as the mix shifted toward chronic and specialty products, manufacturing utilisation improved, and the lower-margin consumer business left. Adjusted EBITDA margin peaked at 36.3% in FY2025, helped by an unusually long 2024/25 Hong Kong influenza season. FY2026 marks an inflection to flat growth. Revenue fell 0.5% and adjusted EBITDA fell 5.4% as cold and flu demand normalised, staff costs rose (+4.8% in cost of sales), and depreciation went up for the revamped Fotan facilities. Attributable profit still rose slightly (+0.3%) thanks to a HK$10.7m drop in finance costs, a HK$11.8m lower tax charge, and higher associate income. That makes FY2026 profit quality somewhat lower than the headline suggests: profit from operations fell 6.2%. Note also that FY2023 profit included a one-off HK$34.2m Employment Support Scheme subsidy.
Balance sheet
Sources: FY2022 AR; FY2023 results; FY2024 results; FY2026 results announcement (balance sheet). FY2023 total liabilities are computed as total assets minus equity. Goodwill is not separately disclosed in the extracts reviewed; intangible assets include capitalised development costs and software. No assets were pledged against bank loans at 31 March 2025 or 2026. All bank loans are in HK$.
Commentary. The balance sheet shrank by about HK$1.9bn between FY2023 and FY2024 because JBM was distributed. Net gearing then fell to a low of 8.3% in FY2025. FY2026 marks a re-leveraging inflection: bank loans rose HK$143.8m (+20.1%) to fund the Fotan revamp and the Tai Po project. Meanwhile cash fell HK$139.2m after HK$230.0m of dividends paid, including the FY2025 special dividend. Net gearing rose to 20.8%. Short-term debt also became much more prominent (current bank loans HK$478.0m vs HK$237.2m), which cut net current assets by 45% to HK$268.7m. Refinancing is not a concern given relationship banking with HSBC, Standard Chartered and Chong Hing, but the maturity profile has clearly shortened. Inventory rose 11.8% for safety stocks at the revamped facilities and for new launches.
Impairment headroom (watch item): The recoverable amount of cash-generating units exceeded carrying amount by HK$825.8m at 31 March 2026. That compares with HK$1,268.3m at 31 March 2025 and HK$1,157.3m (generic CGUs) at 31 March 2024. Management still considers impairment unlikely under reasonably possible changes.
Cash flow
The cash flow statement is in AR FY2026 (page 60), but operating cash flow and free cash flow were not captured in the sources reviewed. They are therefore left blank rather than estimated. No share buybacks were identified in the period. Management describes FY2026 operating cash generation as stable and strong. The FY2024 distribution in specie (fair value HK$564.6m) was non-cash.
Ratios
Commentary. Returns have improved structurally since the JBM separation. ROE moved from single digits to about 12.5%, and ROA more than doubled, because the remaining business is more capital-efficient than the consolidated group was. The long cash conversion cycle (about 172 days, driven by about 150 inventory days) is typical of a multi-SKU generic maker that holds safety stock for public-sector supply obligations. It lengthened in FY2026. Interest coverage is comfortable at 12.7x because Hong Kong rates fell. Net debt to EBITDA of about 0.9x leaves room to fund the HK$607.2m Tai Po contract, but leverage will likely rise further before the plant generates revenue from FY2028 onward.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Generic Drugs / Essential Medicines & Specialty Drugs (HKD Mn) | 1,191.3 | 1,267.6 | 1,467.8 | 1,576.9 | 1,569.5 |
Branded Healthcare, consolidated (HKD Mn) | 404.2 | 518.0 | — | — | — |
Total revenue as reported at the time (HKD Mn) | 1,595.5 | 1,785.6 | 1,467.8 | 1,576.9 | 1,569.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Generic segment YoY revenue growth (%) | 13.6 | 6.4 | 15.8 | 7.4 | -0.5 |
Branded Healthcare YoY revenue growth (%) | 1.8 | 28.2 | — | — | — |
Generic share of reported revenue (%) | 74.7 | 71.0 | 100 | 100 | 100 |
Branded Healthcare share of reported revenue (%) | 25.3 | 29.0 | — | — | — |
Results by Segment and Segment Margins & Growth (%)
| Metric (HKD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Adjusted EBITDA – Generic / continuing (HKD Mn) | 444.2 | 453.1 | 572.8 | 541.6 |
Adjusted EBITDA – Branded Healthcare (HKD Mn) | 124.3 | 82.7 | — | — |
Adjusted EBITDA margin – Generic / continuing (%) | 35.0 | 30.9 | 36.3 | 34.5 |
Profit before tax – continuing (HKD Mn) | — | 254.6 | 373.6 | 362.6 |
PBT margin – continuing (%) | — | 17.3 | 23.7 | 23.1 |
Group Entities
| Entity | Role | Source |
|---|---|---|
Jacobson Pharma Corporation Limited (Cayman) | Listed holding company | AR FY2026 |
Jean-Marie Pharmacal Co. Ltd (HK) | Manufacturing; sponsor of the Tai Po InnoPark smart-factory project | AR FY2026; FY2022 AR |
Ching Mei Drug Company (HK) | Indirect wholly owned subsidiary named as owner of the Tai Po site in the 1 Apr 2026 tender announcement. "Ching Mei" (精美) looks like the Chinese-name transliteration of Jean-Marie, so this is probably the same entity; not confirmed. | HKEX 1 Apr 2026 (via iTiger) |
Europharm Laboratoires Co. Ltd (HK) | Manufacturing (oral solids); Tai Po InnoPark factory; counterparty in Li Chung Shing Tong share purchases | FY2022 AR; HKEX Nov 2024, Oct 2025 |
Medipharma Ltd / Cawah Holdings Ltd | Generic manufacturer acquired in 2016 | ACN Newswire 2016 |
American Unicorn Laboratories | Manufacturer, 100% owned since FY2021 | FY2022 AR |
| — | ATP-licensed logistics; one of two authorised CAR-T handlers in Hong Kong | AR FY2026 |
| — | Has an employee union under PRC labour law | AR FY2026 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 1,595.5 | 1,785.6 | 1,467.8 | 1,576.9 | 1,569.5 |
Revenue, continuing-ops basis (HKD Mn) | 1,191.3 | 1,267.6 | 1,467.8 | 1,576.9 | 1,569.5 |
Cost of sales (HKD Mn) | 975.0 | 1,038.4 | 847.3 | 884.0 | 891.6 |
Gross profit (HKD Mn) | 620.5 | 747.2 | 620.5 | 692.9 | 677.9 |
Profit from operations (HKD Mn) | 260.9 | 410.8 | 333.1 | 414.6 | 388.7 |
Adjusted EBITDA (HKD Mn) | 441.6 | 568.2 | 453.1 | 572.8 | 541.6 |
Finance costs (HKD Mn) | 25.7 | 67.4 | 78.7 | 41.4 | 30.7 |
Profit before tax (HKD Mn) | 231.4 | 339.8 | 254.6 | 373.6 | 362.6 |
Income tax (HKD Mn) | — | — | 44.4 | 72.8 | 61.0 |
Profit for the year (HKD Mn) | 187.7 | 283.2 | 290.8 | 300.8 | 301.6 |
Profit attributable to shareholders (HKD Mn) | 177.7 | 251.0 | 267.0 | 300.8 | 301.6 |
EPS basic (HK cents) | 9.27 | 13.13 | 13.90 | 15.15 | 15.10 |
EPS diluted (HK cents) | 9.27 | 13.13 | 13.90 | 15.15 | 15.10 |
Ordinary DPS (HK cents) | 3.88 | 5.18 | 5.50 | 9.00 | 9.00 |
Special DPS (HK cents) | 0 | 0 | 29.52 | 6.00 | 0 |
Total DPS incl. special (HK cents) | 3.88 | 5.18 | 35.02 | 15.00 | 9.00 |
Business Lines
| Line | FY2025 | FY2026 |
|---|---|---|
Other net income (HKD Mn) | 45.9 | 35.5 |
Selling and distribution expenses (HKD Mn) | 124.0 | 127.3 |
Administrative and other operating expenses (HKD Mn) | 200.3 | 197.5 |
Share of profits of associates (HKD Mn) | 0.4 | 4.7 |
Depreciation (HKD Mn) | 125.2 | 135.7 |
Amortisation of intangibles (HKD Mn) | 18.7 | 18.1 |
Cost of sales – materials (HKD Mn) | 382.7 | 365.5 |
Cost of sales – staff (HKD Mn) | 297.9 | 312.2 |
Cost of sales – other production (HKD Mn) | 203.4 | 213.9 |
Effective tax rate (%) (computed) | 19.5 | 16.8 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 38.9 | 41.8 | 42.3 | 43.9 | 43.2 |
Operating margin, profit from ops / revenue (%) (computed) | 16.4 | 23.0 | 22.7 | 26.3 | 24.8 |
Adjusted EBITDA margin (%) | 27.7 | 31.8 | 30.9 | 36.3 | 34.5 |
Attributable net margin (%) | 11.1 | 14.1 | 18.2 | 19.1 | 19.2 |
Revenue growth, as reported (%) | 10.3 | 11.9 | -17.8 | 7.4 | -0.5 |
Revenue growth, continuing basis (%) | 13.6 | 6.4 | 15.8 | 7.4 | -0.5 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 4,755.5 | 5,380.5 | 3,486.9 | 3,645.2 | 3,563.9 |
Total liabilities (HKD Mn) | 1,797.6 | 2,124.0 | 1,090.5 | 1,167.7 | 1,223.7 |
Total equity (HKD Mn) | 2,958.0 | 3,256.5 | 2,396.4 | 2,477.4 | 2,340.2 |
Equity attributable to shareholders (HKD Mn) | — | — | — | 2,453.2 | 2,316.0 |
Cash and cash equivalents (HKD Mn) | 478.7 | 1,036.4 | 411.9 | 509.0 | 369.9 |
Bank loans – current (HKD Mn) | — | — | 112.8 | 237.2 | 478.0 |
Bank loans – non-current (HKD Mn) | — | — | 592.2 | 476.5 | 379.5 |
Total bank loans (HKD Mn) | 1,341.6 | 1,543.7 | 705.0 | 713.7 | 857.5 |
Lease liabilities (HKD Mn) | — | — | — | 59.5 | 53.4 |
Net debt, bank loans less cash (HKD Mn) | 862.9 | 507.3 | 293.1 | 204.7 | 487.6 |
Net gearing (%) | 29.2 | 15.6 | 12.2 | 8.3 | 20.8 |
Intangible assets incl. goodwill (HKD Mn) | — | — | 435.8 | 421.1 | 427.2 |
Property, plant and equipment (HKD Mn) | — | — | — | 1,494.1 | 1,508.5 |
Investment properties (HKD Mn) | — | — | — | 163.9 | 156.1 |
Other financial assets (HKD Mn) | — | — | — | 398.6 | 349.0 |
Interests in associates (HKD Mn) | — | — | — | 50.8 | 69.9 |
Inventories (HKD Mn) | 314.6 | 368.0 | 317.9 | 332.9 | 372.2 |
Trade and other receivables (HKD Mn) | — | — | 233.4 | 194.4 | 230.9 |
Trade and other payables and contract liabilities (HKD Mn) | — | — | 216.5 | 258.7 | 183.8 |
Current assets (HKD Mn) | — | — | — | 1,038.0 | 986.1 |
Current liabilities (HKD Mn) | — | — | — | 553.1 | 717.4 |
Net current assets / working capital (HKD Mn) | — | — | — | 484.8 | 268.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansDividends & Capital Returns
| Metric | FY2025 | FY2026 |
|---|---|---|
Additions to PP&E and investment properties (HKD Mn) | — | 149.6 |
Capitalised development costs and software (HKD Mn) | — | 24.2 |
Dividends paid in cash (HKD Mn) | 59.6 | 230.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, company-reported (%) | — | — | 10.3 | 12.3 | 12.5 |
ROE, profit / average equity (%) (computed) | 6.5 | 9.1 | — | — | — |
ROA, attributable profit / year-end assets (%) (computed) | 3.7 | 4.7 | 7.7 | 8.3 | 8.5 |
ROIC, after-tax op. profit / (equity + debt + leases − cash) (%) (computed) | — | — | — | 12.2 | 11.2 |
Current ratio (x) (computed) | — | — | — | 1.88 | 1.37 |
Debt / equity, bank loans (x) (computed) | 0.45 | 0.47 | 0.29 | 0.29 | 0.37 |
Net debt / adjusted EBITDA (x) (computed) | 1.95 | 0.89 | 0.65 | 0.36 | 0.90 |
Interest coverage, op. profit / finance costs (x) (computed) | 10.2 | 6.1 | 4.2 | 10.0 | 12.7 |
Asset turnover, revenue / year-end assets (x) (computed) | 0.34 | 0.33 | 0.42 | 0.43 | 0.44 |
Inventory days on COGS (computed) | — | — | 137 | 137 | 152 |
Trade receivable days (computed) | — | — | — | 34 | 41 |
Trade payable days on COGS (computed) | — | — | 22 | 17 | 21 |
Cash conversion cycle, days (computed) | — | — | — | 154 | 172 |
Dividend payout, ordinary + special / attributable profit (%) (computed) | 41.8 | 39.5 | — | 99.7 | 59.7 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong (HKD Mn) | 1,428.4 | 1,552.3 | 1,421.4 | 1,514.6 | 1,514.3 |
Chinese Mainland (HKD Mn) | 80.0 | 156.3 | 33.4 | 34.6 | 23.3 |
Macau (HKD Mn) | 59.6 | 48.1 | 12.9 | 27.6 | 31.6 |
Others (HKD Mn) | 27.5 | 28.9 | 0.1 | 0.1 | 0.2 |
Total (HKD Mn) | 1,595.5 | 1,785.6 | 1,467.8 | 1,576.9 | 1,569.5 |
Geographic Revenue
| Region | FY2025 growth (%) | FY2026 growth (%) | FY2026 share (%) |
|---|---|---|---|
Hong Kong | 6.6 | 0.0 | 96.5 |
Chinese Mainland | 3.6 | -32.7 | 1.5 |
Macau | 114.0 | 14.5 | 2.0 |
Others | 0.0 | 102.0 | 0.0 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price (9–10 Oct 2026) | HK$0.97 | Stockopedia; Simply Wall St |
52-week range | HK$0.94 – HK$1.51 | Simply Wall St |
1-year total shareholder return | −33.1% | Simply Wall St |
3-year total shareholder return | +49.2% | Simply Wall St |
5-year total shareholder return | +61.7% (includes the JBM distribution in specie) | Simply Wall St |
12-month relative strength | −56.3% | Stockopedia |
Capital Markets Data (HKD)
| Metric | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Monthly high (HKD) | 1.780 | 1.619 | 1.530 | 1.510 | 1.490 | 1.330 | 1.310 | 1.280 | 1.280 | 1.250 | 1.230 | 1.150 |
Monthly low (HKD) | 1.600 | 1.420 | 1.400 | 1.440 | 1.340 | 1.220 | 1.230 | 1.230 | 1.190 | 1.110 | 1.120 | 0.980 |
Valuation Multiples
| Multiple | Jacobson | Note |
|---|---|---|
Market cap | HK$1,940m | 2,000.2m shares |
Enterprise value | ≈HK$2,481m |
|
P/E (trailing, FY2026 EPS 15.10c) | 6.4x | Stockopedia forward 12-month: 5.8x |
EV / adjusted EBITDA (FY2026) | 4.6x | Stockopedia: 4.63x |
EV / sales (FY2026) | 1.6x | — |
P/B (attributable equity HK$2,316.0m) | 0.84x | Stockopedia: 0.84x |
Dividend yield (FY2026 DPS 9.0c) | 9.3% | Stockopedia forward: 10.65% |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (HK cents) | 1.20 | 2.80 | 2.50 | 3.50 | 4.25 |
Final DPS (HK cents) | 2.68 | 2.38 | 3.00 | 5.50 | 4.75 |
Special DPS (HK cents) | 0 | 0 | 29.52 | 6.00 | 0 |
Total DPS (HK cents) | 3.88 | 5.18 | 35.02 | 15.00 | 9.00 |
Total dividends for the year (HKD Mn) | — | — | — | 299.8 | 180.0 |
Capital Markets
| Item | Status |
|---|---|
Buyback authorisation | General mandate to repurchase up to 10% of issued shares (excluding treasury shares), renewed at the 11 Aug 2026 AGM; no executed buybacks identified |
Issuance mandate | Up to 20% of issued shares |
Credit ratings (Moody's / S&P / Fitch) | Not rated (none publicly disclosed) |
Debt maturity at 31 Mar 2026 | HK$478.0m due within one year; HK$379.5m due after one year (detailed ladder not captured); all in HK$; unsecured |
Lease liabilities | HK$26.5m current; HK$26.9m non-current |
Analyst Conclusions
Management guidance
No numerical guidance. Management is "optimistic" about the outlook. It cites demographics, chronic disease, primary-care reform (CPP from Q4 2026), patent expiries, the faster drug-approval pathway and GBA integration. It plans to keep pursuing in-licensing, focused R&D in chronic and specialty therapies, manufacturing upgrades (Tai Po first-line trial production by H1 2027), public tenders and community pharmacy initiatives.
Consensus expectations
Consensus revenue and EPS forecasts were not captured. Stockopedia's 12-month rolling forward P/E of 5.8x (versus 6.4x trailing) implies modest expected earnings growth of roughly 10%. That is an inference from the multiples, not a published consensus figure.
Bull case
-
Defensive cash machine priced like a value trap. HK$301.6m of attributable profit, a 34.5% adjusted EBITDA margin and ROE of about 12.5% are valued at 6.4x P/E, 4.6x EV/EBITDA and 0.84x book, with a 9.3% yield. Even no growth supports a re-rating.
-
Specialty mix shift. 46 in-licences in FY2026, a 241-product pipeline, biosimilars and the CAR-T niche can lift growth back to the 7% continuing-revenue CAGR of FY2023–FY2026 once the flu effect has passed.
-
Policy tailwinds and capacity. CPP, CDF and CDCC broaden private and community demand just as the Tai Po plant (10 smart lines) arrives in 2027–2029, adding capacity and potentially exports.
Bear case
-
Growth has stalled and leverage is rising. Revenue −0.5%, profit from operations −6.2% and adjusted EBITDA −5.4% in FY2026, while net gearing rose to 20.8% before a HK$607.2m capex programme that will not earn revenue until FY2028 or later.
-
Concentration risk. About 51% of revenue comes from one public buyer and about 97% from Hong Kong. Any Hospital Authority procurement or pricing reform hits earnings directly.
-
Governance discount persists. A founder-controlled board (70.25% stake), a combined Chair/CEO, recurring connected transactions with JBM, INED turnover, and a 25-point drop in CGU impairment headroom all justify a structural discount.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Late Nov 2026 | H1 FY2027 interim results: watch revenue trend against the normalised H1 FY2026 base, gross margin, and the interim DPS (4.25c last year) |
| Q4 2026 onward | Community Pharmacy Programme rollout and Jacobson's role in it |
| Winter 2026/27 | Severity of the influenza season (cold and flu sales) |
| H1 2027 | Tai Po first-line trial production; capex spend against the HK$607.2m contract |
| Ongoing | New in-licensing deals, biosimilar launches, CAR-T case volume (4 to date) |
| Ongoing | Net gearing path; refinancing of HK$478m in current bank loans |
| Ongoing | Board independence after the Aug 2026 INED change; connected transactions with JBM |
| Jun 2027 | FY2027 results and dividend decision (any special dividend?) |
| Ongoing | Any use of the 10% buyback mandate at sub-book valuations |
Analyst verdict
Jacobson Pharma has finished turning itself from a mixed generics and consumer-brands group into a focused Hong Kong essential-medicines franchise, and the financial results back up that choice. On a continuing basis, revenue grew at about 7% a year from FY2023 to FY2026. Gross margin widened to about 43%, attributable profit rose to a record HK$301.6m, and ROE roughly doubled from pre-separation levels. Its competitive position rests on being the largest local generic supplier, owning nine GMP facilities, holding a large registration book and pipeline, and controlling distribution into almost every public and private prescriber. That position is hard to copy in a small market that multinationals mostly ignore.
The market's de-rating, about 33% over a year to roughly 6x earnings and below book value, reflects three real concerns rather than mispricing alone. First, FY2026 showed that underlying growth is fragile without help from a strong flu season. Second, the company is entering a capex-heavy phase (HK$607m-plus at Tai Po) funded by more short-term bank debt, with returns that will not arrive until 2027–2029. Third, governance remains founder-centric, with recurring related-party dealings involving JBM.
We would describe the equity as a high-yield, low-multiple defensive holding with execution-dependent upside. At HK$0.97, the about 9% cash yield and about 15% earnings yield provide meaningful downside support, as long as Hospital Authority pricing stays rational and leverage stays below roughly 1.5x EBITDA. A re-rating needs evidence that the specialty and in-licensing engine can deliver mid-single-digit organic growth in a normal flu year, starting with the November 2026 interim results, and that Tai Po stays on budget. Investors should also watch for any narrowing of the governance discount, for example through buyback use, splitting the Chair and CEO roles, or fewer connected transactions. Without these, the stock may stay a cheap income vehicle rather than a compounding story.
Dossier compiled from public filings and market data accessible as of 11 October 2026. no figures have been estimated except where explicitly labelled "(computed)" or "inference".
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Board tenure | Committees | Background (as disclosed) | Age |
|---|---|---|---|---|---|
Mr. Sum Kwong Yip, Derek | Chairman and CEO; Executive Director; founder | Since establishment | Executive Committee (Chair) | Founder; has managed the group's business and strategic planning since establishment; controlling shareholder of both Jacobson and JBM Healthcare | Not captured |
Mr. Yim Chun Leung | Executive Director; authorised representative | Not captured | Executive, ESG (left Nomination 28 Jul 2025) | Brother-in-law of former INED Prof. Lam Sing Kwong, Simon | Not captured |
Ms. Pun Yue Wai | Executive Director; authorised representative | Not captured | Executive, Remuneration, Nomination (from 28 Jul 2025) | Only female director | Not captured |
Prof. Wong Chi Kei, Ian | Non-executive Director | Not captured | — | Academic (details not captured) | Not captured |
Dr. Lam Kwing Tong, Alan | INED; served more than 9 years | Since 30 Aug 2016 | Remuneration (Chair since 21 Sep 2016), Audit, Nomination | Private dental practice; BDS (Glasgow, 1987); MGDS RCS Edinburgh (1999); Hong Kong Dental Academy membership (2013); fee HK$230,000 a year; deemed interest in 600,000 shares | 63 |
Mr. Luk Ting Lung, Alan | INED | Since 28 Jul 2025 | ESG Committee (Chair), Audit; also chairs Risk Management Committee per AGM circular | 39+ years in financial services: MD of Hobbit Family Office; CEO of Hobbit Asset Management; Hang Seng Bank Head of Private Banking and Trust (2010–2021); American Express Bank (1999–2008, incl. Alternate CEO); Schroders; HSBC Investment Bank. MBA (Murdoch), MSc Global Finance (HKUST/NYU Stern). Also INED of JBM (Healthcare) (2161) since Jan 2021. Fee HK$230,000 a year. | 64 |
Mr. Young Chun Man, Kenneth | INED (former) | Until 11 Aug 2026 | Former Audit and Nomination Chair; Remuneration member | Accounting and finance expert (Listing Rule 3.10(2)); retired citing other business commitments | Not captured |
Prof. Lam Sing Kwong, Simon | INED (former) | Retired 28 Jul 2025 | Former ESG Chair; Audit member | — | Not captured |
New INED (appointed at or after the 11 Aug 2026 AGM) | INED | From Aug 2026 | Committee changes announced | — | — |
Directors' Remuneration
| Emolument band (HKD) | Number of directors |
|---|---|
Nil – 1,000,000 | 5 |
3,000,001 – 4,000,000 | 1 |
7,000,001 – 8,000,000 | 1 |
19,000,001 – 20,000,000 | 1 |
Major Shareholders
| Holder | Shares (long) | % of issued shares | Date of notice |
|---|---|---|---|
Mr. Sum Kwong Yip, Derek (personal, corporate and deemed interests) | 1,405,238,000 | 70.25 | 22 Jan 2026 |
Queenshill Development Limited | 508,404,000 | 25.42 | 3 Apr 2025 |
Mr. Yim Chun Leung (ED) | 46,820,000 | 2.34 | 22 Jan 2026 |
Ms. Pun Yue Wai (ED) | 10,810,000 | 0.54 | 22 Jan 2026 |
Dr. Lam Kwing Tong, Alan (INED) | 600,000 (deemed) | 0.03 | AGM circular, Jul 2026 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
28 Jul 2025 | Prof. Lam Sing Kwong, Simon retired as INED; Mr. Luk Ting Lung, Alan appointed INED, Audit member and ESG Chair; Mr. Yim left Nomination Committee; Ms. Pun joined | Board refresh; nomination terms of reference revised |
23 Jun 2026 | Mr. Young Chun Man, Kenneth announced he would not seek re-election | Other business commitments; no disagreement with the board |
11 Aug 2026 | Mr. Young retired; INED appointment and committee changes announced | — |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with Jacobson | Revenue (latest disclosed) | Relative positioning |
|---|---|---|---|---|
Hospital Authority multi-source tenders (all bidders) | Market structure | Public generic tenders | — | One buyer sets prices; Jacobson is the largest local supplier |
Sandoz (global generics) | Multinational generics | HK generic registrations and tenders | Global; HK not disclosed | Global scale; selective HK portfolio |
Teva Pharmaceutical | Multinational generics | HK generics | Global; HK not disclosed | Selective HK presence |
Viatris | Multinational generics and brands | HK chronic-disease generics | Global; HK not disclosed | Branded-generic focus |
Local HK manufacturers (e.g., Vickmans Laboratories, Universal Pharmaceutical Laboratories) | Private local generic makers | HK public and private generics | Not publicly disclosed (private) | Smaller; Jacobson's share was more than the next two combined (2016) |
JBM (Healthcare) Ltd (2161.HK) | Former subsidiary; consumer health and proprietary Chinese medicine | Limited (OTC and pharmacy channel) | HK$834.6m (FY Mar 2026); +6.7% | Same controlling shareholder; complementary more than competing |
Lee's Pharmaceutical (0950.HK) | HK-listed specialty and in-licensing pharma | In-licensed specialty drugs, HK/China | HK$1,436m (FY Dec 2025); +2.6% | Stronger China and R&D presence; lower margins |
China Medical System (0867.HK) | Specialty in-licensing and commercialisation | Specialty in-licensing model (mainly Mainland) | RMB8,212m (FY Dec 2025); +10.0% | Much larger; Mainland-focused |
Zuellig Pharma; DKSH | Distributors / logistics | Pharmaceutical logistics, cold chain, in-licensed distribution | Not disclosed for HK | Compete for principals' distribution mandates |
Other licensed CAR-T / ATP handler (one other in HK) | Logistics | ATP handling | — | Duopoly in HK CAR-T handling |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Jacobson (FY Mar 2026) | JBM Healthcare (FY Mar 2026) | Lee's Pharm (FY Dec 2025) | China Medical System (FY Dec 2025) |
|---|---|---|---|---|
Revenue | HK$1,569.5m | HK$834.6m | HK$1,436m | RMB8,212m |
Revenue growth | −0.5% | +6.7% | +2.6% | +10.0% |
Gross margin | 43.2% | 55.8% | 50.8% | 71.5% |
Operating margin | 24.8% (company) / 24.7% (S&P) | 31.6% | 7.7% | 19.2% |
Net margin | 19.2% | 24.1% | 6.4% | 18.1% |
R&D intensity (expensed) | ≈0.0% (most development capitalised) | — | 7.7% (HK$111.0m) | 7.1% (RMB585.0m) |
“—” = not publicly disclosed.
Recent Developments
All of them are listed below, with immediately preceding context items flagged.



